PL3230289T3 - Pochodne 7-(morfolinylo)-2-(n-piperazynylo)metylotieno[2, 3-c]pirydyny jako leki przeciwnowotworowe - Google Patents

Pochodne 7-(morfolinylo)-2-(n-piperazynylo)metylotieno[2, 3-c]pirydyny jako leki przeciwnowotworowe

Info

Publication number
PL3230289T3
PL3230289T3 PL14841337T PL14841337T PL3230289T3 PL 3230289 T3 PL3230289 T3 PL 3230289T3 PL 14841337 T PL14841337 T PL 14841337T PL 14841337 T PL14841337 T PL 14841337T PL 3230289 T3 PL3230289 T3 PL 3230289T3
Authority
PL
Poland
Prior art keywords
piperazinyl
morpholinyl
anticancer drugs
pyridine derivatives
methyl thieno
Prior art date
Application number
PL14841337T
Other languages
English (en)
Inventor
Durga Prasad Konakanchi
Subba Rao Pula
Rama Krishna Pilli
Lakshmana Viswa Venkata Pavan Kumar MADDULA
Srinivasa Krishna Murthy Konduri
Janaki Rama Rao Ravi
Naga Vasanta Srinivasu VUPPALAPATI
Sandeep Kumar THOOTA
Pulla Reddy Muddasani
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of PL3230289T3 publication Critical patent/PL3230289T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
PL14841337T 2014-12-11 2014-12-11 Pochodne 7-(morfolinylo)-2-(n-piperazynylo)metylotieno[2, 3-c]pirydyny jako leki przeciwnowotworowe PL3230289T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14841337.0A EP3230289B1 (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c]pyridine derivatives as anticancer drugs
PCT/IN2014/000770 WO2016092556A1 (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Publications (1)

Publication Number Publication Date
PL3230289T3 true PL3230289T3 (pl) 2020-03-31

Family

ID=52595387

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14841337T PL3230289T3 (pl) 2014-12-11 2014-12-11 Pochodne 7-(morfolinylo)-2-(n-piperazynylo)metylotieno[2, 3-c]pirydyny jako leki przeciwnowotworowe

Country Status (31)

Country Link
US (1) US10106554B2 (pl)
EP (1) EP3230289B1 (pl)
JP (1) JP6454419B2 (pl)
KR (1) KR102328921B1 (pl)
CN (1) CN107074873B (pl)
AP (1) AP2017009749A0 (pl)
AU (1) AU2014413483B2 (pl)
BR (1) BR112017005518B1 (pl)
CA (1) CA2959980C (pl)
CO (1) CO2017002266A2 (pl)
CY (1) CY1122080T1 (pl)
DK (1) DK3230289T3 (pl)
EA (1) EA036819B1 (pl)
ES (1) ES2750268T3 (pl)
HR (1) HRP20192041T1 (pl)
HU (1) HUE047144T2 (pl)
IL (1) IL252254B (pl)
LT (1) LT3230289T (pl)
MA (1) MA40110B2 (pl)
MX (1) MX2017004782A (pl)
MY (1) MY188946A (pl)
NZ (1) NZ729078A (pl)
PH (1) PH12017500342A1 (pl)
PL (1) PL3230289T3 (pl)
PT (1) PT3230289T (pl)
RS (1) RS59409B1 (pl)
SG (1) SG11201702162PA (pl)
SI (1) SI3230289T1 (pl)
UA (1) UA117318C2 (pl)
WO (1) WO2016092556A1 (pl)
ZA (1) ZA201701036B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851426B2 (en) * 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
AU2020406139A1 (en) 2019-12-20 2022-06-30 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
CN117529325A (zh) * 2021-04-21 2024-02-06 纳特科药品有限公司 制备7-(吗啉基)-2-(N-哌嗪基)甲基噻吩并[2,3-c]吡啶衍生物的改进方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579526A (en) 1968-11-13 1971-05-18 Research Corp Preparation of thienopyridines
FR2411838A1 (fr) 1977-12-19 1979-07-13 Parcor Nouveaux derives des thieno (2-3-c) et (3,2-c) pyridines, leurs procede de preparation et leur application therapeutique
US4839365A (en) 1987-05-19 1989-06-13 Shinogi & Co., Ltd. Thienopyridine derivatives useful in treating gastric ulcers
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
WO2007122410A1 (en) * 2006-04-26 2007-11-01 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
GB0608264D0 (en) * 2006-04-26 2006-06-07 Piramed Ltd Pharmaceutical compounds
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
JP5511786B2 (ja) 2008-03-31 2014-06-04 ジェネンテック, インコーポレイテッド ベンゾピランおよびベンゾキセピンpi3k阻害剤化合物および使用方法
JP5452617B2 (ja) * 2009-01-08 2014-03-26 キュリス,インコーポレイテッド 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター
EP2483272A4 (en) 2009-09-29 2013-09-18 Xcovery Holding Co Llc SELECTIVE PI3K (DELTA) INHIBITOR
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
BR112013020329A2 (pt) * 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase

Also Published As

Publication number Publication date
JP2017537139A (ja) 2017-12-14
AP2017009749A0 (en) 2017-02-28
CN107074873B (zh) 2022-01-07
IL252254A0 (en) 2017-07-31
EA036819B1 (ru) 2020-12-23
ZA201701036B (en) 2019-06-26
US20170320891A1 (en) 2017-11-09
PH12017500342A1 (en) 2017-07-17
MA40110B2 (fr) 2020-12-31
CN107074873A (zh) 2017-08-18
SI3230289T1 (sl) 2019-10-30
HUE047144T2 (hu) 2020-04-28
IL252254B (en) 2019-08-29
PT3230289T (pt) 2019-10-30
UA117318C2 (uk) 2018-07-10
NZ729078A (en) 2021-07-30
RS59409B1 (sr) 2019-11-29
MY188946A (en) 2022-01-14
EP3230289B1 (en) 2019-08-14
BR112017005518B1 (pt) 2022-11-29
CA2959980A1 (en) 2016-06-16
AU2014413483B2 (en) 2019-07-25
MX2017004782A (es) 2017-07-27
AU2014413483A1 (en) 2017-03-09
CO2017002266A2 (es) 2017-05-31
MA40110A1 (fr) 2017-12-29
EA201791294A1 (ru) 2017-11-30
SG11201702162PA (en) 2017-04-27
US10106554B2 (en) 2018-10-23
KR20170090434A (ko) 2017-08-07
EP3230289A1 (en) 2017-10-18
BR112017005518A2 (pt) 2017-12-05
DK3230289T3 (da) 2019-10-28
KR102328921B1 (ko) 2021-11-19
HRP20192041T1 (hr) 2020-02-07
CY1122080T1 (el) 2020-11-25
JP6454419B2 (ja) 2019-01-16
LT3230289T (lt) 2019-10-10
WO2016092556A1 (en) 2016-06-16
CA2959980C (en) 2023-04-25
ES2750268T3 (es) 2020-03-25

Similar Documents

Publication Publication Date Title
HK1244804A1 (zh) 4h-吡咯並[3,2-c]吡啶-4-酮衍生物
IL252065A0 (en) Thiano[2,3-c]pyrrol-4-ion derivatives as erk inhibitors
IL251441B (en) History of imidazo pyridine and pharmaceutical preparations containing them
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
IL251780B (en) Derivatives of 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-h1-pyrrolo[c-3,2] pyridine and pharmaceutical preparations containing them
IL251067B (en) 4-(phenyl/heteroaryl)-7-(phenyl/pyrid-4-yl)-8,5-dihydro-8,5-ethanopyrido[4,3-d]pyrimidine derivatives and pharmaceutical preparations containing them
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
IL250267A0 (en) History of indolizine, their preparation and pharmaceutical preparations containing them
IL252578B (en) History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
IL252254A0 (en) Anticancer drugs derived from 7-morpholinyl-2-n-piperazinyl-methyl thiano-[3,2-c]-pyridine
IL252579B (en) History of methyl-(1h-pyrazolo-4-yl-)-3-methyl-1h-pyrazolo[3,4-d]pyrimidine and pharmaceutical preparations containing them
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
IL243739A0 (en) History of 1h-pyrazolo[4,3-b]pyridine and their pharmaceutical preparations for the treatment of proliferative disorders
EP3150584A4 (en) 3,4-dihydroquinazoline derivative and complex preparation containing same
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
GEP20197016B (en) 7-(morpholinyl)-2-(n-piperazinyl)methyl thieno[2,3-c]pyridine derivatives as anticancer drugs
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS